RxDoctor Payments Data

Rebeca Juarbe Arrillaga

Internal Medicine · Palatka, FLNPI 1619125259

Payments from drug & device makers

$821in general payments, 2019–2025

Across 45 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$311
  • Medtronic$171
  • Exact Sciences$96
  • Lilly USA, LLC$90
  • AbbVie$58
  • AstraZeneca$49
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$821 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$258,588
Medicare patients
509
Services billed
3,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide81$156,807
OzempicSemaglutide84$124,104
JardianceEmpagliflozin55$68,465
EliquisApixaban26$37,654
FarxigaDapagliflozin Propanediol16$20,287
VraylarCariprazine Hcl12$17,454
RybelsusSemaglutide12$17,209
JanuviaSitagliptin Phosphate17$15,581
Breo ElliptaFluticasone/Vilanterol13$9,384
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,696
Omeprazole130$2,876
Albuterol Sulfate HfaAlbuterol Sulfate62$2,817
Testosterone Cypionate36$1,948
Levothyroxine Sodium217$1,910
Gabapentin94$1,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$90$156,80781 claims
Novo NordiskOzempic, Rybelsus$311$141,31396 claims
AstraZenecaFarxiga$49$20,28716 claims
AbbVieVraylar, Synthroid$58$18,33628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palatka

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →